Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination

Transplantation Proceedings

Volumn 41, Issue 10, 2009, Pages 4138-4146

  Cataneo Davila A ^a   Zuniga Varga J ^a   Correa Rotter, R ^a   Alberu J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ALBUMINURIA; CADAVER; CALCINEURIN; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SIROLIMUS; TIME FACTORS; TISSUE DONORS;

EID: 71249155677     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.08.065     Document Type: Article

References (28)

1. Pascual M., Theruvath T., Hawai T., et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 580
2. Davis C.L. Transplant: immunology and treatment of rejection. Am J Kidney Dis 43 (2004) 1116
3. Monaco A., and Morris P. Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican) [Editorial]. Transplantation 79 suppl 3 (2005) S67
4. Solez K., Colvin R.B., Racusen M.H., et al. Banff 07 classification of renal allograft pathology: update and future directions. Am J Transplant 8 (2008) 753
5. Olyaei A., de Mattos A., and Bennett W. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7 (2001) 384
6. Neumayer H. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 79 suppl 3 (2005) S72
7. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36
8. Huang S., and Houghton P. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3 (2003) 371
9. Dancey J.E. Inhibitors of the mammalian target of rapamycin. Exp Opin Invest Drugs 14 (2005) 313
10. Chapman T., and Perry C. Everolimus. Drugs 64 (2004) 861
11. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 24 (2002) 53
12. Pilmore H., and Dittmer I. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 16 (2002) 191
13. Weir M., Ward M., Blahut S., et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59 (2001) 1567
14. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
15. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87 (2009) 233
16. Lorber M., Ponticelli C., Whelchel J., et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy and safety data. Clin Transplant 19 (2005) 145
17. Holdaas H., Bentdal Ø., Pfeffer P., et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. [published online ahead of print February 12, 2008]. Clin Transplant 22 (2008) 366
18. Pascual J., Boletis I.N., and Campistol J. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage and future directions. Transplant Rev 20 (2006) 1
19. Keane W.F. Proteinuria: its clinical importance and role in progressive kidney disease. Am J Kidney Dis 35 (2000) S97
20. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
21. Sennesael J.J., Bosmans J.L., Bogers J.P., et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 80 (2005) 1578
22. 2+ from intracellular stores. Hypertension 29 (1997) 222
23. Morales J., Fierro A., Benavente D., et al. Conversion from a calcineurin inhibitor-based immunosuppresive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 39 (2007) 591
24. Halimi J.-M., Buchler M., Al-Najjar A., et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 7 (2007) 2775
25. Shihab F.S., Bennett W.M., Yi H., et al. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-[beta] 1. Transplantation 77 (2004) 683
26. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2003) 231
27. Pohanka E. Conversion to everolimus in maintenance patients: current clinical strategies. Nephrol Dial Transplant 21 suppl 3 (2006) iii24
28. Van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261